Search results

Also bare in mind that dosing was split between 3 groups (200,400,600mg) and in the conference call they said the 600mg dose had "a more consistent and more robust effect as compared to other doses". This is where I see the main hope in the results.

Also bare in mind that dosing was split between 3 groups (200,400,600mg) and in the conference call they said the 600mg dose had "a more consistent and more robust effect as compared to other doses". This is where I see the main hope in the results.

James, Kalydeco (VX-770) achieved results of a 10.5% mean absolute improvement in its phase 3 trial, not 20% as mentioned above. This trial was also a far longer trial (48 weeks) compaerd to the recent 809/770 phase II trial. Unfortunately, the phase 2 study of VX-770 in G551 did nt use lung...

James, Kalydeco (VX-770) achieved results of a 10.5% mean absolute improvement in its phase 3 trial, not 20% as mentioned above. This trial was also a far longer trial (48 weeks) compaerd to the recent 809/770 phase II trial. Unfortunately, the phase 2 study of VX-770 in G551 did nt use lung...

Yes, the 46% over 5% FEV increase also includes the 30% that saw a 10% increase. It must be noted though that the study was split into three groups - all had the same dosage of kalydeco (vx-770) but the VX-809 dosage was varied between the three groups (200mg,400mg,600mg). They would nt say in...

Yes, the 46% over 5% FEV increase also includes the 30% that saw a 10% increase. It must be noted though that the study was split into three groups - all had the same dosage of kalydeco (vx-770) but the VX-809 dosage was varied between the three groups (200mg,400mg,600mg). They would nt say in...